Innovation, Experience, and Quality

Article

The One Use-Plus SBK, the new generation of LASIK microkeratomes, achieves accuracy and visual results equivalent to femtolasers at a fraction of the cost.

For nearly two centuries, Moria has developed, manufactured, and distributed sophisticated, high quality, innovative ophthalmic surgical instrumentation and equipment that contribute to improved surgical outcomes.

The One Use-Plus SBK, the new generation of LASIK microkeratomes, achieves accuracy and visual results equivalent to femtolasers… at a fraction of the cost. The One Use-Plus SBK produces predictable, thin flaps with planar profiles, resulting in outstanding visual outcomes that are equivalent or better than those attained with a femtolaser. This excellent performance is achieved with less discomfort to the patient, none of the complications associated with the laser, and at a significantly lower cost to the refractive practice.

Working closely with leading corneal surgeons, Moria has been at the forefront of the DSAEK revolution and helped make it the surgical procedure of choice for posterior corneal pathologies. Today Moria, more than ever, is keeping ahead with a promising new technique, Ultra-Thin DSAEK.

The One® range of single-use, high precision, hand-held surgical instruments provide increased safety, convenience, and efficiency in cataract surgery. It’s the guarantee of 100% cleanliness and sterility for each patient and the guarantee of new, precise, undamaged instruments for each procedure.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.